Dec 13, 2024 6:15pm EST Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
Nov 12, 2024 4:30pm EST Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates